Alzheimer's Researchers Urge Trial Participation Following Fiona Phillips' Diagnosis
核心洞察
Researchers are advocating for increased participation in Alzheimer's drug trials, highlighting potential benefits for participants regardless of treatment efficacy.
Fiona Phillips, diagnosed with early-onset Alzheimer's, is participating in a trial for miridesap, a novel drug targeting SAP (搜索) to break down amyloid plaques (搜索).
Experts emphasize the need for diversified research approaches, increased funding, and improved diagnostic tools to advance Alzheimer's treatment.
Following the public disclosure by TV presenter Fiona Phillips of her early-onset Alzheimer's diagnosis and participation in a drug trial, researchers are emphasizing the critical need for increased participation in Alzheimer's drug trials. Experts suggest that involvement in clinical trials can improve outcomes for individuals with dementia (搜索), irrespective of the drug's effectiveness.
Benefits of Trial Participation
Prof. Jonathan Schott, a neurologist at UCL and Alzheimer's Research UK (搜索)'s chief medical officer, stated, "We are certainly firm believers that the way forward is to take part in research." He highlighted that trial participants benefit from access to experts and contribute to advancing the understanding of dementia (搜索). While acknowledging the high failure rate of drug trials, Schott expressed optimism about future breakthroughs in Alzheimer's treatment.
Miridesap Trial Details
Phillips is participating in a trial for miridesap, a novel drug designed to remove serum amyloid P component (SAP (搜索)) from the brain, which binds to amyloid plaques (搜索). The goal is to accelerate the breakdown of these plaques and slow the progression of Alzheimer's. The trial, now in its third year, involves 43 participants, with ongoing research into side effects and safety. Phillips is blinded to whether she is receiving miridesap or a placebo but believes her condition may be stabilizing.
The Need for Increased Funding and Better Diagnostics
Schott noted that miridesap represents a "relatively early-stage and very novel treatment," differing from other promising drugs like lecanemab. He stressed the importance of developing personalized treatments for Alzheimer's, similar to cancer therapies, which requires significantly more funding for dementia (搜索) research. Sian Gregory of the Alzheimer's Society, also pointed out the NHS's lack of sufficient diagnostic tools, such as PET scans and blood marker and spinal fluid testing, to provide timely, specific and accurate diagnoses, which are needed to access treatments.
Early-Onset Alzheimer's and the Importance of Early Diagnosis
Early-onset Alzheimer's, affecting an estimated 70,800 people in the UK, can be challenging to diagnose due to its atypical symptoms and confusion with other midlife issues. Osman Shabir, a researcher at the University of Sheffield, noted that early diagnosis allows for better stabilization and reduced disease progression. Increased awareness and reduced stigma are encouraging more people to seek early diagnosis.